[{"address1": "345 Park Avenue South", "address2": "6th Floor", "city": "New York", "state": "NY", "zip": "10010", "country": "United States", "phone": "212 547 9879", "website": "https://www.lexeotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.", "fullTimeEmployees": 61, "companyOfficers": [{"maxAge": 1, "name": "Mr. R. Nolan Townsend", "age": 43, "title": "CEO & Director", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 3741748, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric  Adler M.D.", "age": 50, "title": "Chief Medical Officer & Head of Research", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 2705659, "exercisedValue": 0, "unexercisedValue": 112845}, {"maxAge": 1, "name": "Dr. Jose Manuel Otero Ph.D.", "age": 45, "title": "Chief Technical Officer", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 2987030, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ronald G. Crystal M.D.", "title": "Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jenny R. Robertson J.D.", "age": 49, "title": "Chief Legal Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 617900, "exercisedValue": 0, "unexercisedValue": 94692}, {"maxAge": 1, "name": "Mr. Jordan M. Baumhardt Ph.D.", "title": "Vice President of Corporate Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sandi See Tai M.D.", "age": 53, "title": "Chief Development Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.78, "open": 4.83, "dayLow": 4.8, "dayHigh": 5.11, "regularMarketPreviousClose": 4.78, "regularMarketOpen": 4.83, "regularMarketDayLow": 4.8, "regularMarketDayHigh": 5.11, "payoutRatio": 0.0, "forwardPE": -1.7689531, "volume": 504575, "regularMarketVolume": 504575, "averageVolume": 524753, "averageVolume10days": 359750, "averageDailyVolume10Day": 359750, "bid": 3.66, "ask": 6.2, "bidSize": 2, "askSize": 2, "marketCap": 264605888, "fiftyTwoWeekLow": 1.45, "fiftyTwoWeekHigh": 12.33, "fiftyDayAverage": 4.3646, "twoHundredDayAverage": 4.630825, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 140607200, "profitMargins": 0.0, "floatShares": 29378358, "sharesOutstanding": 54001200, "sharesShort": 5249721, "sharesShortPriorMonth": 5150197, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.097200006, "heldPercentInsiders": 0.00447, "heldPercentInstitutions": 0.89309996, "shortRatio": 11.34, "shortPercentOfFloat": 0.1066, "impliedSharesOutstanding": 54001200, "bookValue": 2.56, "priceToBook": 1.9140626, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -114172000, "trailingEps": -3.21, "forwardEps": -2.77, "enterpriseToEbitda": -1.145, "52WeekChange": -0.56675506, "SandP52WeekChange": 0.1513431, "quoteType": "EQUITY", "currentPrice": 4.9, "targetHighPrice": 28.0, "targetLowPrice": 9.0, "targetMeanPrice": 16.375, "targetMedianPrice": 17.5, "recommendationMean": 1.375, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 132893000, "totalCashPerShare": 2.461, "ebitda": -122818000, "totalDebt": 8913000, "quickRatio": 4.206, "currentRatio": 4.433, "debtToEquity": 6.449, "returnOnAssets": -0.41912997, "returnOnEquity": -0.7532, "grossProfits": -73681000, "freeCashflow": -53553000, "operatingCashflow": -95067000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "LXEO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "regularMarketChangePercent": 2.51046, "regularMarketPrice": 4.9, "earningsTimestamp": 1754884800, "earningsTimestampStart": 1762950600, "earningsTimestampEnd": 1762950600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.21, "epsForward": -2.77, "epsCurrentYear": -2.13887, "priceEpsCurrentYear": -2.2909293, "fiftyDayAverageChange": 0.5353999, "fiftyDayAverageChangePercent": 0.12266872, "twoHundredDayAverageChange": 0.26917505, "twoHundredDayAverageChangePercent": 0.058126803, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "corporateActions": [], "postMarketTime": 1755902611, "regularMarketTime": 1755892800, "exchange": "NGM", "messageBoardId": "finmb_625814286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Lexeo Therapeutics, Inc.", "longName": "Lexeo Therapeutics, Inc.", "ipoExpectedDate": "2023-11-03", "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1699018200000, "postMarketChangePercent": 0.0, "postMarketPrice": 4.9, "postMarketChange": 0.0, "regularMarketChange": 0.12, "regularMarketDayRange": "4.8 - 5.11", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 524753, "fiftyTwoWeekLowChange": 3.45, "fiftyTwoWeekLowChangePercent": 2.3793104, "fiftyTwoWeekRange": "1.45 - 12.33", "fiftyTwoWeekHighChange": -7.43, "fiftyTwoWeekHighChangePercent": -0.60259527, "fiftyTwoWeekChangePercent": -56.675507, "displayName": "Lexeo Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-08-23"}]